{"id":34476,"date":"2024-11-26T16:35:45","date_gmt":"2024-11-26T16:35:45","guid":{"rendered":"https:\/\/bnssghealthiertogether.org.uk\/?page_id=34476"},"modified":"2025-01-16T10:25:46","modified_gmt":"2025-01-16T10:25:46","slug":"epitope-evaluating-the-population-impact-of-hepatitis-c-direct-acting-antiviral-treatment-as-prevention-for-people-who-inject-drugs","status":"publish","type":"page","link":"https:\/\/bnssghealthiertogether.org.uk\/tr\/integrated-care-board\/research-and-evidence\/our-research-portfolio\/nihr-funded-projects\/epitope-evaluating-the-population-impact-of-hepatitis-c-direct-acting-antiviral-treatment-as-prevention-for-people-who-inject-drugs\/","title":{"rendered":"EPIToPe: Uyu\u015fturucu Enjekte Eden Ki\u015filerde Hepatit C&#039;nin \u00d6nlenmesinde Do\u011frudan Etkili Antiviral Tedavinin Pop\u00fclasyon \u00dczerindeki Etkisinin De\u011ferlendirilmesi"},"content":{"rendered":"<div class=\"assembler_default-group assembler_module_group assembler_default-group_1 assembler_module_group_1\"><div class=\"assembler_module_area assembler_module_area_1\"><div class=\"assembler_text-module assembler_module assembler_text-module_1 assembler_module_1  transparent\"><a tabindex=\"-1\" title=\"Mod\u00fcl-1 ba\u015fl\u0131kl\u0131 b\u00f6l\u00fcm\" id=\"module-1\" href=\"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/pages\/34476\/#module-1\" class=\"anchor\"><span class=\"hidden\">Mod\u00fcl-1 ba\u015fl\u0131kl\u0131 b\u00f6l\u00fcm<\/span><\/a><!-- Template found for text-module - Template: template-text - Matched: _only --><section class=\"w-full mx-auto max-w-content pt-12 sm:pt-24 pb-12 sm:pb-24\">\r\n  <div class=\"entry-content w-full !px-0 max-w-small\">\r\n        <header class=\"local_header\">\n<div class=\"local_header__inner\">\n<h1 class=\"local_header__title\">EPIToPe: Uyu\u015fturucu Enjekte Eden Ki\u015filerde Hepatit C&#039;nin \u00d6nlenmesinde Do\u011frudan Etkili Antiviral Tedavinin Pop\u00fclasyon \u00dczerindeki Etkisinin De\u011ferlendirilmesi<\/h1>\n<\/div>\n<\/header>\n<article class=\"page_content\">\n<h2><\/h2>\n<h2 class=\"page_content__inner\">Finansman<\/h2>\n<\/article>\n<p>Ulusal Sa\u011fl\u0131k Enstit\u00fcs\u00fc (NIHR) Uygulamal\u0131 Ara\u015ft\u0131rma Program\u0131 Hibeleri (PGfAR) Ref. RP-PG-0616-20008<\/p>\n<h2>Ara\u015ft\u0131rma sorusu nedir?<\/h2>\n<p>Uyu\u015fturucu enjekte eden ki\u015filer aras\u0131nda Hepatit C Vir\u00fcs\u00fc (HCV) tedavisinin yayg\u0131nla\u015ft\u0131r\u0131lmas\u0131, pop\u00fclasyondaki HCV prevalans\u0131n\u0131 ve bula\u015fmas\u0131n\u0131 azalt\u0131r m\u0131?<\/p>\n<h2>Sorun nedir?<\/h2>\n<p>\u0130ngiltere&#039;de yakla\u015f\u0131k 200.000 ki\u015finin Hepatit C Vir\u00fcs\u00fc (HCV) ile enfekte oldu\u011fu tahmin ediliyor; bu vir\u00fcs karaci\u011fer hastal\u0131\u011f\u0131, kanser ve \u00f6l\u00fcmlerin \u00f6nemli bir nedenidir.<\/p>\n<p>Birle\u015fik Krall\u0131k&#039;taki HCV enfeksiyonlar\u0131n\u0131n \u00e7o\u011fu, uyu\u015fturucu enjekte eden ki\u015filerde g\u00f6r\u00fclmektedir. Yeni HCV ila\u00e7lar\u0131, az say\u0131da yan etkiyle 12 hafta i\u00e7inde hastalar\u0131n 1&#039;inden fazlas\u0131n\u0131 iyile\u015ftirmektedir, ancak pahal\u0131d\u0131r (20.000 \u00a3&#039;dan fazla) ve \u015fu anda yaln\u0131zca orta veya \u015fiddetli karaci\u011fer hastal\u0131\u011f\u0131 olan ki\u015filerde kullan\u0131lmaktad\u0131r.<\/p>\n<p>Matematiksel modeller, HCV&#039;nin &quot;tedaviyle \u00f6nlenmesi&quot;, yani uyu\u015fturucu enjekte eden ve hafif karaci\u011fer hastal\u0131\u011f\u0131 olan ki\u015filerin HCV a\u00e7\u0131s\u0131ndan tedavi edilmesinin, uyu\u015fturucu enjekte eden baz\u0131 ki\u015filerin yeniden enfekte olmas\u0131na ra\u011fmen, pop\u00fclasyondaki yeni HCV enfeksiyonlar\u0131n\u0131n genel say\u0131s\u0131n\u0131 azaltabilece\u011fini \u00f6ne s\u00fcrmektedir.<\/p>\n<p>Ayr\u0131ca, HCV tedavisi yeterince art\u0131r\u0131l\u0131rsa, HCV sonunda \u0130ngiltere n\u00fcfusundan &quot;ortadan kald\u0131r\u0131lacakt\u0131r&quot;. Bu modellerden elde edilen bulgular\u0131n hastalar \u00fczerinde test edilmesi gerekmektedir.<\/p>\n<h2>Ara\u015ft\u0131rman\u0131n amac\u0131 nedir?<\/h2>\n<p>HCV modellerinden elde edilen bulgular\u0131n hastalar \u00fczerinde test edilmesi gerekmektedir. Bu \u00e7al\u0131\u015fma, uyu\u015fturucu enjekte eden ve hafif karaci\u011fer hastal\u0131\u011f\u0131 olan ki\u015filerin HCV a\u00e7\u0131s\u0131ndan tedavi edilmesinin bu pop\u00fclasyonda HCV&#039;yi azalt\u0131p azaltamayaca\u011f\u0131n\u0131 ara\u015ft\u0131racakt\u0131r.<\/p>\n<h2>Bu nas\u0131l ba\u015far\u0131lacak?<\/h2>\n<p>\u0130lk \u00e7al\u0131\u015fmada, Dundee\/NHS Tayside b\u00f6lgesinde iki y\u0131l i\u00e7inde en az 500 ki\u015fiye enjeksiyon yoluyla uyu\u015fturucu tedavisi uygulamay\u0131 hedefliyoruz. Hepatit C tedavisindeki bu b\u00fcy\u00fck ve h\u0131zl\u0131 art\u0131\u015f, eczaneler, ba\u011f\u0131ml\u0131l\u0131k hizmetleri ve cezaevleri de dahil olmak \u00fczere toplumdaki bir\u00e7ok noktada ger\u00e7ekle\u015ftirilecektir.<\/p>\n<p>Tahminlerimize g\u00f6re bu, Dundee&#039;de uyu\u015fturucu enjekte eden ki\u015filerde kronik HCV oran\u0131n\u0131 yakla\u015f\u0131k 301.000&#039;den 101.000&#039;in alt\u0131na d\u00fc\u015f\u00fcrerek \u00fc\u00e7te iki oran\u0131nda azaltacakt\u0131r.<\/p>\n<p>N\u00fcfustaki HCV de\u011fi\u015fimlerini \u00f6l\u00e7mek i\u00e7in, Tayside&#039;da ve Birle\u015fik Krall\u0131k&#039;\u0131n geri kalan\u0131nda uyu\u015fturucu enjekte eden ki\u015filerden elde edilen anketlerden elde edilen verileri art\u0131rmam\u0131z ve HCV&#039;nin zaman i\u00e7inde de\u011fi\u015fip de\u011fi\u015fmedi\u011fine dair tarafs\u0131z tahminler sa\u011flayabilecek yeni istatistiksel y\u00f6ntemler geli\u015ftirmemiz gerekiyor.<\/p>\n<p>Dundee\/NHS Tayside&#039;daki hizmet sa\u011flay\u0131c\u0131larla g\u00f6r\u00fc\u015ferek, di\u011fer merkezlerin HCV tedavisini ba\u015far\u0131l\u0131 bir \u015fekilde yayg\u0131nla\u015ft\u0131rmas\u0131na yard\u0131mc\u0131 olabilecek temel engelleri ve kolayla\u015ft\u0131r\u0131c\u0131 fakt\u00f6rleri belirleyece\u011fiz.<\/p>\n<p>Tedavi sonras\u0131nda hastalarla g\u00f6r\u00fc\u015fmeler yapaca\u011f\u0131z ve idari veri tabanlar\u0131yla ba\u011flant\u0131 kurarak, HCV&#039;den iyile\u015fmenin, enjeksiyon yoluyla uyu\u015fturucu kullanan ki\u015filerin uzman uyu\u015fturucu tedavisine devam etmelerine ve ba\u011f\u0131ml\u0131l\u0131ktan kurtulmalar\u0131na yard\u0131mc\u0131 olup olmad\u0131\u011f\u0131n\u0131 de\u011ferlendirece\u011fiz. Ayr\u0131ca, enjeksiyon yoluyla uyu\u015fturucu kullanan ki\u015filer i\u00e7in HCV tedavisindeki art\u0131\u015f\u0131n NHS (Ulusal Sa\u011fl\u0131k Sistemi) i\u00e7in maliyet etkin olup olmad\u0131\u011f\u0131n\u0131 da tahmin edece\u011fiz.<\/p>\n<p>Son olarak, \u0130ngiltere&#039;de HCV tedavileri artt\u0131k\u00e7a, b\u00f6lgesel HCV klinik hizmetleriyle birlikte HCV &quot;Tedaviyle \u00d6nleme&quot; yakla\u015f\u0131m\u0131n\u0131n ikinci ve daha b\u00fcy\u00fck bir de\u011ferlendirmesini birlikte tasarlayaca\u011f\u0131z. \u0130lk \u00e7al\u0131\u015fmam\u0131zdan elde edilen kan\u0131tlar\u0131 kullanarak, toplumda HCV tedavisini nas\u0131l yayg\u0131nla\u015ft\u0131rabilece\u011fimizi ve HCV enfeksiyonlar\u0131n\u0131n, HCV tedavisinin daha yo\u011fun bir \u015fekilde yayg\u0131nla\u015ft\u0131r\u0131ld\u0131\u011f\u0131 b\u00f6lgelerde mi yoksa daha az yo\u011fun bir \u015fekilde yayg\u0131nla\u015ft\u0131r\u0131ld\u0131\u011f\u0131 b\u00f6lgelerde mi daha fazla azald\u0131\u011f\u0131n\u0131 belirleyece\u011fiz.<\/p>\n<h2>Ara\u015ft\u0131rmay\u0131 kim y\u00fcr\u00fct\u00fcyor?<\/h2>\n<p>Prof. Matt Hickman, Bristol \u00dcniversitesi Halk Sa\u011fl\u0131\u011f\u0131 ve Epidemiyoloji B\u00f6l\u00fcm\u00fc, N\u00fcfus Sa\u011fl\u0131\u011f\u0131 Bilimleri Profes\u00f6r\u00fc.<\/p>\n<h2>Daha fazla bilgi:<\/h2>\n<p><a href=\"https:\/\/www.bristol.ac.uk\/population-health-sciences\/projects\/epitope\/\" target=\"_blank\" rel=\"nofollow noopener\">EPITOPE Hakk\u0131nda<\/a><\/p>\n<p>Daha fazla bilgi almak veya bu projeye kat\u0131lmak i\u00e7in l\u00fctfen e-posta g\u00f6nderin. <a href=\"mailto:bnssg.research@nhs.net\" target=\"_blank\" rel=\"noopener\">bnssg.research@nhs.net<\/a>.<\/p>\n<p>Burada ifade edilen g\u00f6r\u00fc\u015fler yazar(lar)a aittir ve NIHR veya Sa\u011fl\u0131k ve Sosyal Bak\u0131m Bakanl\u0131\u011f\u0131&#039;n\u0131n g\u00f6r\u00fc\u015flerini yans\u0131tmayabilir.<\/p>\n  <\/div>\r\n  <\/section><\/div><!-- .assembler_text-module.assembler_module.assembler_text-module_1.assembler_module_1..transparent --><\/div><!-- .assembler_module_area.assembler_module_area_1 --><\/div><!-- .assembler_default-group.assembler_module_group.assembler_default-group_1.assembler_module_group_1  -->","protected":false},"excerpt":{"rendered":"<p>Section titled module-1 EPIToPe: Evaluating the Population Impact of Hepatitis C Direct Acting Antiviral Treatment as Prevention for People Who Inject Drugs Funding National Institute for Health (NIHR) Programme Grants for Applied Research (PGfAR) Ref. RP-PG-0616-20008 What is the research question? Does scaling-up Hepatitis C Virus (HCV) treatment among People Who Inject Drugs (PWID) reduce [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":32881,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"tags":[],"class_list":["post-34476","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/pages\/34476","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/comments?post=34476"}],"version-history":[{"count":4,"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/pages\/34476\/revisions"}],"predecessor-version":[{"id":36109,"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/pages\/34476\/revisions\/36109"}],"up":[{"embeddable":true,"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/pages\/32881"}],"wp:attachment":[{"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/media?parent=34476"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/tags?post=34476"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}